Table 5.
Virological responses* among HIV-2 –infected patients in 17 studies
| Study | VL | VL | VL | VL | Delta of VL | Slope of VL (first period) | Slope of VL (second period) | Other response |
|---|---|---|---|---|---|---|---|---|
| (Author, year) | Threshold | Baseline | Month-12 | Month -24 | ||||
| % non detectable | N, Median [IQR] | n, Median [IQR] | n, Median [IQR] | |||||
| Adje-Touré, 2003 [35] | NR | 4.5 (4.1-5.2) | 4.1 (3.2-4.9) | NR | NR | NR | NR | |
| Van Der Ende, 2003 [28] | <2.7 log10 (10%) | NR | NR | NR | NR | NR | NR | At week 23, 13/18 (72%) had VL <2.7 log10 |
| Mullins 2004 | <2.0 cp log10 | NR | NR | NR | NR | NR | NR | Median viral load at the last visit 3.51 [3.27-4.43] log10 |
| Matheron, 2006 [47] | NR | 3.1 (1.7-4.2) | 1.7 (1.7-2.9) | 1.7 (1.7-1.7) | 12 months: -0.6 (-1.7; 0.0) | |||
| 24 months | ||||||||
| -0.6 (-2.5; 0) | ||||||||
| Ndour, 2006 [41] | NR | NR | NR | NR | NR | NR | NR | NR |
| Drylewicz, 2008 [12] | <2.7 | 2.9 | NR | NR | NR | <2 months | >2 months | |
| (34%) | (2.4-3.7) | -0.62 (-0.84; - 0.40) log10 cp/ml/month | 0.02 (-0.27; 0.32) | |||||
| log10 cp/ml/year | ||||||||
| Ruelle 2008 [46] | 4.1 | PI based regimen 8/13 (62%) undectable Without PI 1/6 (17%) undectable | PI based regimen 5/8 (63%) undectable Without PI 1/4 (25%) undectable | |||||
| (3.4-4.8) | ||||||||
| Benard A, 2009 [26] | NR | 3.3 | 3 months (n = 20) 80% had undectable VL | |||||
| N = 24 (33%) | [3.0-3.8] | |||||||
| Jallow, 2009 [32] | <2.0 log10 | 4.9 [4.6-5.2] | NR | NR | NR | NR | NR | NR |
| Gottlieb, 2009 [29] | <1.4 log10 N = 23 (30%) | 2.0 [<1.4-4.3] | NR | NR | NR | NR | NR | No resistance |
| 9/11 (82%) had VL <1.4 | ||||||||
| Resistance 3/12 (25%) had VL <1.4 | ||||||||
| Harries, 2010 [17] | NR | NR | NR | NR | NR | NR | NR | NR |
| Drylewicz 2010 [36] | NR | NR | NR | NR | NR | NR | NR | NR |
| Smith 2010 [42] | <1.4 log10 | 2.5 [1.6-4.3] | NR | NR | NR | NR | NR | 35% (n = 74) had detectable RNA plasma HIV-2 at their last follow-up visit. Median 100 [31–1997] copies/ml |
| Chiara, 2010 [48] | NR | NR | NR | NR | NR | NR | NR | NR |
| Peterson 2011 [18] | NR | 4.9 [4.2-5.4] | 81% VL <400 | 89% VL <400 | NR | NR | NR | 19% expressed viral rebound by 36 months |
| Benard, 2011 [15] | <2.7 log10 | PI: 4.0 [3.4-4.6] 3NRTIs 4.0 [2.9-4.6] | PI: 2.2 3NRTIs 4.0 | NR | NR | 0-3 months | 3-12 months | |
| N = 110 (39%) | PI: -0.3 log10/ml/months | PI: -0.002 log10/ml/months | ||||||
| 3 NRTIs: -0.2 log10/ml/months | 3 NRTIs: - +1.6 log10/ml/months | |||||||
| Peterson K, 2012 (56) | NR | NR | NR | NR | NR | NR | NR | NR |
*Included only the studies which reported virological responses.
NR: Not Reported, VL: viral load.